Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age

NCT04520659 ↗

Phase 1 Completed 81 enrolled National Institute of Allergy and Infectious Diseases (NIAID) Sanofi Pasteur, a Sanofi Company · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to evaluate the infectivity, safety, and immunogenicity of a single dose of a recombinant, live-attenuated respiratory syncytial virus (RSV) vaccine, LID/ΔM2-2/1030s, in RSV-seronegative infants and children 6 to 24 months of age.

Timeline

Start: 2022-03-16
Primary completion: 2024-04-18
Completion: 2024-04-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LID/ΔM2-2/1030s	Vaccine	100000 unknown	Other

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age

Summary

Timeline

Drugs

Indications